Next year will see clinical trials in the United States and Europe of a newly approved Chinese drug for the treatment of "Alzheimer's", in an effort to document the first medicine that China is talking about to treat terminal illness.
Lee Blohe, vice president of Shanghai Green Valley Pharmaceuticals, quoted by Bloomberg News as saying that treatment is being planned for about 2,046 patients in a mild to moderate stage of Alzheimer's disease in 200 locations in North America, Europe and the Asia Pacific region. , For 18 months.
Last month, the National Administration of Medicinal Products of China announced conditional approval of oligomanit. According to the attached medical leaflet, patients will need three capsules twice a day. The cost of treatment per week is 895 yuan (128 dollars).
The company revealed its new plans at a press conference in the Chinese capital, Beijing, today, nearly two months after it made headlines around the world by announcing the approval of the regulatory authorities in China for the first new treatment for "Alzheimer's" to be announced in 17 years.
It is noteworthy that this company is unknown outside China, and its announcement of the new treatment was met with great skepticism, given the great speed with which it has managed to achieve a puzzling achievement for the pharmaceutical industry giants around the world for decades.
It is noteworthy that conditional approval means that the company is still required to conduct further studies on how the treatment works, along with safety and long-term efficacy.
The company announced that it intends to invest three billion dollars over the next ten years in order to implement these requirements, including conducting experiments at the global level.